MedImmune lowers FluMist guidance
Executive Summary
MedImmune reduces fourth quarter and full-year revenue guidance based on low demandfor its intranasal flu vaccine FluMist. Vaccine now expected to bring in $55 mil.-$85 mil. for 2003 instead of $120-$140 mil; total revenue expectations for the year reduced to $1.04 bil.-$1.1 bil. from $1.1 bil-$1.15 bil. MedImmune expects to record $10 mil. in FluMist "manufacturing supply goal payments and contractual reimbursements" in the fourth quarter and "manufacturing transfer payments and royalties" in the range of $7 mil-$37 mil. Wyeth has provisions in place for accepting FluMist returns (1"The Pink Sheet" Nov. 17, 2003, p. 35)...
You may also be interested in...
Wyeth Offering FluMist Coupons; Prevnar Supply Issue “Resolved,” FDA Says
Wyeth and MedImmune plan to increase couponing for FluMist in the coming months
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.